Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial

- Male or female, age 12 to less than 18 years at the time of signing informed consent
and less than 18 years at date of randomisation

- BMI corresponding to equal to or above 30 kg/m^2 for adults by international cut-off
points and equal or above the 95th percentile for age and sex (for diagnosis of
obesity)

- Stable body weight during the previous 90 days before screening V2 (below 5 kg
self-reported weight change)

- History of failing to lose sufficient weight with lifestyle modification as judged by
the investigator and documented in subject's medical record

Exclusion Criteria:

- Pre-pubertal subjects (Tanner stage 1) at screening V2

- Type 1 diabetes mellitus (T1DM)

- Family or personal history of multiple endocrine neoplasia type 2 (MEN2)

- Medullary thyroid carcinoma (MTC)

- History of pancreatitis (acute or chronic)

- Subjects with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine
causes)

- Treatment with medications within 90 days before screening V2 that, based on the
investigator's judgement, may cause significant weight change. This should also
include treatment with any of the following medications: pramlintide, orlistat,
zonisamide, topiramate, lorcaserin, phenteremine, bupropion, naltrexone, glucagon-like
peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity)

- Anti-diabetic treatment other than metformin

- History of major depressive disorder within 2 years before screening V2